ImmuneWatch (Belgium) – Strategic-Technological Analysis
35 pages · PDF · 20 August 2025 · Licensed single-user copy, watermarked to the buyer
Tactical Biotechnology, Human Enhancement & MedTech Artificial Intelligence, Big Data & Analytics Belgium
€499 excl. VAT — EU VAT calculated at checkout (VAT ID accepted for reverse charge); invoice issued after payment
One click to Stripe — guest checkout, no account. Your download appears on the confirmation page and arrives by e-mail right after payment (link valid 72 hours, up to 5 downloads).
About this report
In an era where biotechnology and artificial intelligence converge as pillars of security and healthcare, one Belgian start-up is quietly positioning itself at this critical nexus. ImmuneWatch, a young spin-off from the University of Antwerp and its university hospital, has developed a platform to decode one of immunology’s most complex puzzles: understanding T-cell receptors and their targets .
By making vast immune repertoire data clinically actionable through machine learning, this Antwerp-based venture is accelerating the design of vaccines and immunotherapies . Its technology emerged from years of academic research, yet its implications stretch far beyond the lab.
Key questions this report answers
- How does ImmuneWatch's machine-learning platform decode T-cell receptors and their targets to accelerate vaccine and immunotherapy design?
- How mature is its immune-repertoire technology, spun off from the University of Antwerp, and what is its biosecurity relevance?
- Who are its partners and customers at the biotech-AI-security nexus?
- What capability gaps and dependencies affect this Belgian biotech start-up?
Inside this report
- Executive Summary
- 1. Corporate Identity & Legal Structure
- 2. Strategic Business Profile
- 3. Technology Portfolio Mapping
- 4. Technology Readiness Assessment
- 5. European Strategic Program Participation
- 6. Academic & Research Origins
- 7. Dual-Use Applications & European Market Strategy
- 8. Strategic Partnerships & European Industrial Alliances
- 9. European Market Focus & Operational Domains
- 10. Intellectual Property & European Innovation Assets
- 11. Leadership & European Technical Expertise
- 12. Capability and Gap Analysis
- 13. Strategic Indicators & European Innovation Metrics
Who it's for
Investors screening ImmuneWatch, competitors and partners assessing their position, and analysts who need a sourced, structured account of the entity and its technology.
Related reports
Methodology, format & delivery
DFM reports are built from primary and official sources — TED procurement notices, CORDIS and the EU Funding & Tenders Portal, EIB operations, the NATO Innovation Fund portfolio, SIPRI data, official budget documents and company disclosures — read together with the underlying legal texts. Sources are cited in the document; it reflects them as of its publication date (20 August 2025). You receive a 35-page PDF, watermarked to you on every page, delivered on the confirmation page and by e-mail immediately after checkout (personal link valid 72 hours, up to 5 downloads). Guest checkout, single-user licence — Terms of Sale.
Related on DFM
More Tactical reports · Biotechnology, Human Enhancement & MedTech · Artificial Intelligence, Big Data & Analytics · All reports
Prefer unlimited access?
Prefer unlimited access? Every report like this is included in the DFM Analysis subscription. See plans →